Lilly retatrutide more than doubles Ozempic weight loss in Phase 3 diabetes trial
Topline TRANSCEND-T2D-2 data show the investigational triple agonist cut A1C by 2.2 points and drove roughly 20 percent weight loss, while Lilly prepares a 2027 FDA filing.